Supreme Court temporarily restores mifepristone access amid legal battle over abortion drug
Primary region US
Tags Justice · Policy
Regions US
Justice Samuel Alito issued a temporary stay on May 4, 2026, blocking a Fifth Circuit Court of Appeals ruling that had limited online and mail-order access to mifepristone, the drug used in roughly two-thirds of US abortions. The Fifth Circuit's decision would have restricted telemedicine prescriptions and pharmacy distribution. Alito gave Louisiana until May 7 to respond; the stay is in effect through May 11 while the full Court considers the emergency appeal. Pharmaceutical manufacturers Danco and GenBioPro argued the Fifth Circuit ruling created 'regulatory chaos' for the FDA's drug approval system. The case has major implications for national abortion access and the scope of FDA authority.
Strategic interpretation
The temporary stay preserves the status quo while the full Court deliberates, but Justice Alito's order of a compressed schedule (state response by May 7, stay through May 11) suggests an expedited decision timeline. The case tests whether the Court's conservative majority will extend its Dobbs rollback of abortion rights to restrict a medication that accounts for the majority of abortions nationally. The FDA jurisdiction angle adds a novel regulatory dimension: if courts can override FDA-approved drug protocols based on state objections, it could destabilize the national drug approval framework beyond the abortion context. The outcome will significantly influence the 2026 midterm elections as abortion access remains a mobilizing issue for Democratic voters.